STAT

International trial uses AI to rapidly identify optimal Covid-19 treatments

A major study seeks to turn frenetic attempts to save lives into a running international experiment, with the goal of quickly identifying optimal treatments for #coronavirus patients.
Source: Gene J. Puskar/AP

Treating patients with the never-before-seen Covid-19 is forcing doctors to choose between two equally unpalatable options: try an unproven therapy and hope it works, or treat patients with standard supportive care for severe respiratory disease until a randomized controlled trial establishes the best treatment.

But maybe the choice doesn’t have to be so stark.

A randomized controlled trial ramping up in dozens of hospitals around the world proposes a third way — fusing those two approaches together by using artificial intelligence to home in on the most effective treatments on the fly.

The study seeks to turn frenetic attempts to save is an effective therapy and, if so, for which types of patients. The trial will also allow the researchers to test multiple therapies at once.

You’re reading a preview, subscribe to read more.

More from STAT

STAT1 min read
STAT+: Health Care Leaders Plot How To Expand Diversity In Clinical Trials
Experts gathered at the Milken Institute Global Conference this week to discussed potential strategies to expand diversity in clinical trials. Here are some of their big ideas.
STAT1 min read
STAT+: Senate Drug Shortage Bill Would Pay Hospitals Bonuses For Good Contracting Practices
A bipartisan Senate bill takes a new approach to persistent drug shortages: have Medicare pay bonuses to hospitals and physicians for contracting that ensures a steady supply.
STAT2 min readCrime & Violence
STAT+: Pharmalittle: We’re Reading About A Medicare Price-negotiation Ruling, Pharma’s Slipping Reputation, And More
A U.S. judge dealt a blow to two drugmakers challenging the authority for Medicare to negotiate the prices of prescription drugs.

Related Books & Audiobooks